Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Mylan Inc    MYL   US6285301072

MYLAN INC (MYL)

49
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Mylan Inc. : Before the Bell Scans of MYL, TEVA, COV, VRX, and ZTS

05/09/2013 | 02:50am US/Eastern
Recommend:
0

StockCall.com Provides Stock Research on Mylan Inc., Teva Pharmaceutical Industries Ltd, Covidien plc, Valeant Pharmaceuticals International Inc., and Zoetis Inc.

New York City, New York -- (May 09, 2013)

Equity markets edged higher on Wednesday after struggling initially. It was yet another historic day as the Dow Jones and the S&P 500 closed at fresh all-time high levels. Market sentiment was lifted by better-than-expected trade data from China. Improving global economic outlook coupled with ultra-loose monetary policies from developed world central banks have boosted investors? risk appetite. Yesterday, the healthcare sector was among the best performers in the S&P 500. Among the major movers in this sector were Mylan Inc. (NASDAQ: MYL), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Covidien Plc (NYSE: COV), Vertex Pharmaceuticals International Inc. (NYSE: VRX), and Zoetis Inc. (NYSE: ZTS). StockCall has taken an interest in these companies and you can now sign up to download the free technical research on MYL, TEVA, COV, VRX, and ZTS at

www.stockcall.com/registration

Mylan Inc.?s shares edged lower in trading on Wednesday. The stock traded between $29.30 and $29.93 before finishing the day 1.21% lower at $29.33 on volume of 4.41 million. Despite the losses yesterday, Mylan?s shares have gained nearly 1.50% in the last three trading sessions. Year-to-date, the stock has gained more than 6.80%, underperforming the broad market. Shares of MYL are currently trading more than 6% below their 52-week high. Sign up today to read the free research report on MYL at

www.StockCall.com/MYL050913.pdf

Shares of Teva Pharmaceutical Industries Ltd. edged higher in yesterday?s trading session; however, the gains were limited. The stock closed 0.18% higher at $38.42 on volume of 2.94 million. Teva Pharmaceutical?s shares are currently trading close to their 52-week low of $38.33. The stock is also trading below its 50-day and 200-day moving averages which is a bearish signal. However, the stock?s MACD has just crossed above the signal line which suggests that market sentiment has turned bearish. Register to download the free technical analysis on TEVA at

www.StockCall.com/TEVA050913.pdf

Shares of Covidien Plc edged higher on Wednesday, tracking gains in the broad market. The stock touched an intraday high of $65.88 before finishing the day 0.98% higher at $65.88 on volume of 2.89 million. Covidien?s shares have gained nearly 2.40% in the last three trading sessions. The stock has seen a series of highs over the past week which is a bullish signal. The positive trend is further confirmed by recent volume activity, and the stock?s MACD chart. Free report on COV can be accessed by registering at

www.StockCall.com/COV050913.pdf

Valeant Pharmaceuticals International Inc.?s shares struggled in yesterday?s trading session. The stock ended the day 0.28% lower at $73.86 on volume of 713,719. The company?s shares are currently trading close to their 52-week high of $76.57. The stock has gained nearly 23.60% so far in 2013 as compared to a gain of nearly 14.50% for the S&P 500. The stock is currently trading above its 50-day and 200-day moving averages.Register withStockCall and download the research on VRX for free at

www.StockCall.com/VRX050913.pdf

Shares of Zoetis Inc. rose in trading on Wednesday. The stock touched an intra-day high of $33.44 before finishing the day 1.16% higher at $33.26 on volume of 1.03 million. Zoetis?shares have underperformed the S&P 500 so far in 2013, gaining nearly 7.50%. The stock?s MACD is currently trading above the signal line and the zero-line which is a bullish signal. Shares of ZTS are trading nearly 6% below their 52-week high. Read the full free research on ZTS by signing up to StockCall at

www.StockCall.com/ZTS050913.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

www.stockcall.com

Contact Person:

William T. Knight

Email: info@stockcall.com

Contact Number: (646) 396-9857 (9:00 am EST ? 01:30 pm EST)


© Accesswire 2013
Recommend :
0
React to this article
Latest news on MYLAN INC
53m ago MYLAN : Wins Motion for Temporary Restraining Order Against Apotex for Authorize..
1d ago EXCLUSIVE - INDIA'S LUPIN, U.S. FIRM : sources
1d ago India's Lupin, U.S. firms weigh bids for GSK's mature drugs -sources
4d agoDJRoche Not Interested in Large Acquisitions, Says CEO -- Report
5d ago MYLAN : More Tax Inversions: Abbott Selling Part of Generic Drug Business to Myl..
6d ago MYLAN : Says It Wins Motion To Enjoin GSK From Providing Paroxetine CR To Apotex
6d ago MYLAN : Wins Motion to Enjoin GlaxoSmithKline from Providing Paroxetine CR to Ap..
7d ago MYLAN : Launches Generic Micardis® Tablets
7d ago Sanofi held talks with Abbott, Mylan about mature drugs - document
07/14 Wall St. closes higher on Citi earnings, healthcare M&A
Advertisement
Chart
Duration : Period :
Mylan Inc Technical Analysis Chart | MYL | US6285301072 | 4-Traders
Income Statement Evolution
Mylan Inc : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF